| Teton Medical Center | |
|
915 4th St Nw, Choteau, MT 59422-9123 | |
| (406) 466-5763 | |
| (406) 466-5852 |
| Full Name | Teton Medical Center |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 915 4th St Nw, Choteau, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477681989 | NPI | - | NPPES |
| 3100357 | Medicaid | MT | |
| 311597 | Medicaid | MT | |
| 4108143 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Teton Medical Center 915 4th St Nw, Choteau, MT 59422-9123 Ph: (406) 466-5763 | Teton Medical Center 915 4th St Nw, Choteau, MT 59422-9123 Ph: (406) 466-5763 |
News Archive
The clinical phenotype of COVID-19, caused by SARS-CoV-2, is remarkable for its wide range of severity among individual patients. Genetic variations are known to mediate part of these differences. To examine these differences, researchers in a new study used human induced pluripotent stem cells (iPSCs) from different genetically diverse individuals. These cells are used to model genetic disease since they contain the donor's genetic information. Researchers use a panel of iPSCs from over 500 individuals. The researchers preferred undifferentiated iPSCs to reduce the time required to differentiate them, especially since infection is not always reliable.
A team of researchers led by David J. Mooney, Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences, have identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast cancer.
Use of the pulmonary artery catheter decreased by 65 percent in the U.S. between 1993 and 2004, possibly due to growing evidence that this invasive procedure does not reduce the risk of death for hospitalized patients, according to a study in the July 25 issue of JAMA .
Scientists from Wake Forest University School of Medicine have identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. The research is reported in the current issue of Molecular Cancer Research.
A protein called CK2 plays a deadly role in colorectal carcinoma by blocking the ability of these tumors to activate a natural self-destruct mechanism that would clear this cancer from the body. This finding, by researchers at St. Jude Children's Research Hospital, is currently published in the online edition of Oncogene.
› Verified 1 days ago
Ms. Pamela Ann Wedum, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 38 1st Ave Sw, Choteau, MT 59422 Phone: 406-466-2548 |